MAZ (MYC associated zinc finger protein) is a transcriptional regulator that plays important roles in cancer biology and cellular processes. In hepatocellular carcinoma associated with non-alcoholic fatty liver disease (NAFLD-HCC), MAZ shows enriched activity alongside MYC, suggesting its involvement in activated transcriptional regulation in liver cancer 1. MAZ has been identified as one of nine M2 macrophage-related prognostic genes in prostate cancer, where it contributes to a risk signature associated with tumor progression and immune characteristics 2. The gene appears to function in concert with MYC in transcriptional networks, particularly in cancer contexts where dysregulated transcription factors drive tumorigenesis. While the provided abstracts demonstrate MAZ's involvement in cancer-related transcriptional programs and its utility as a prognostic biomarker, detailed mechanistic information about its specific DNA-binding properties, target genes, and molecular interactions is limited in these studies. The clinical significance of MAZ extends to its potential use in risk stratification and prognosis prediction in both liver and prostate cancers, though more research is needed to fully characterize its therapeutic implications.